Drew Ranieri
Stock Analyst at Morgan Stanley
(1.24)
# 3,586
Out of 4,902 analysts
167
Total ratings
45.56%
Success rate
-12.59%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GMED Globus Medical | Maintains: Overweight | $75 → $68 | $57.55 | +18.16% | 13 | Jul 15, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $4 → $6 | $4.36 | +37.61% | 4 | Mar 5, 2025 | |
| ATEC Alphatec Holdings | Assumes: Equal-Weight | $9.5 → $10 | $10.63 | -5.93% | 10 | Dec 2, 2024 | |
| SYK Stryker | Upgrades: Overweight | $370 → $445 | $388.90 | +14.43% | 9 | Dec 2, 2024 | |
| SIBN SI-BONE | Maintains: Overweight | $21 → $19 | $16.75 | +13.43% | 15 | Aug 6, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $11.98 | +125.38% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $5.79 | +38.17% | 12 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $25.49 | -13.69% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $9.08 | -11.89% | 13 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $75 → $83 | $17.60 | +368.75% | 10 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $19.75 | +92.41% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $73.45 | +30.70% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $11.64 | +123.37% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $180.90 | +63.07% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $113.59 | +146.50% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $6.49 | -22.96% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $27.89 | +150.99% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $516.16 | -41.88% | 6 | Apr 25, 2022 |
Globus Medical
Jul 15, 2025
Maintains: Overweight
Price Target: $75 → $68
Current: $57.55
Upside: +18.16%
Organogenesis Holdings
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $4 → $6
Current: $4.36
Upside: +37.61%
Alphatec Holdings
Dec 2, 2024
Assumes: Equal-Weight
Price Target: $9.5 → $10
Current: $10.63
Upside: -5.93%
Stryker
Dec 2, 2024
Upgrades: Overweight
Price Target: $370 → $445
Current: $388.90
Upside: +14.43%
SI-BONE
Aug 6, 2024
Maintains: Overweight
Price Target: $21 → $19
Current: $16.75
Upside: +13.43%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $11.98
Upside: +125.38%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $5.79
Upside: +38.17%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $25.49
Upside: -13.69%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $9.08
Upside: -11.89%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $75 → $83
Current: $17.60
Upside: +368.75%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $19.75
Upside: +92.41%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $73.45
Upside: +30.70%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $11.64
Upside: +123.37%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $180.90
Upside: +63.07%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $113.59
Upside: +146.50%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $6.49
Upside: -22.96%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $27.89
Upside: +150.99%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $516.16
Upside: -41.88%